

# NERVIANO MEDICAL SCIENCES

## Nerviano Medical Sciences Srl Launches China Subsidiary to Advance Oncology Pipeline and ADC Portfolio

**Nerviano, Italy – Shanghai, China 1 August 2025** — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced today the expansion of its presence in Asia with the establishment of **Nerviano Medical Sciences (Shanghai) Ltd.**

The new subsidiary, incorporated in **Shanghai**, places NMS in one of the world's fastest-growing hubs for biotechnology and pharmaceutical innovation. With strong government backing, increased investment, and a deep focus on R&D, Shanghai is rapidly becoming a powerhouse for life sciences in Asia and beyond.

*"I am thrilled that NMS is expanding its global reach into China, following the successful launch of our U.S. affiliate in 2023," said [Hugues Dolgos](#), Pharm.D, CEO of NMS Group and NMS Srl. "We've already assembled a clinical team to support key clinical trials in China, along with a business development team focused on leveraging the dynamic Asian ecosystem, fostering innovation, and building strategic partnerships to accelerate our **clinical pipeline and ADC (antibody-drug conjugate) portfolio.**"*

*Leading the new subsidiary is **Dadong Li, Ph.D.**, CEO of NMS Shanghai, who added, "I'm honored to open our first office in China and look forward to submitting our first IND in China to enroll patients in 2026 for our highly innovative assets. I'm especially proud to welcome **Dr. Yaling Huang**, a talented physician-scientist, as Global Clinical Lead—demonstrating our commitment to delivering breakthrough cancer treatments to patients in China and around the world where unmet needs remain."*

With this milestone, NMS reinforces its mission to bring forward life-changing oncology therapies on a global scale.

---

### About Nerviano Medical Sciences

[Nerviano Medical Sciences S.r.l.](#) focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.

NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production.

# NERVIANO MEDICAL SCIENCES

Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets

For more information, visit <https://www.nervianoms.com>.

**Media Relations:** [mediarelations@nervianoms.com](mailto:mediarelations@nervianoms.com)